Pacira Biosciences, Inc. (PCRX) — 10-Q Filings
All 10-Q filings from Pacira Biosciences, Inc.. Browse 5 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (5)
-
Pacira Swings to Profit on Strong Sales, Reduced Impairments
— Nov 6, 2025 Risk: medium
Pacira BioSciences, Inc. reported a significant turnaround in Q3 2025, achieving net income of $5.432 million, a stark improvement from a net loss of $143.466 m -
Pacira BioSciences Files Q1 2025 10-Q
— May 8, 2025 Risk: medium
Pacira BioSciences, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and business operations, including produc -
Pacira BioSciences Files Q3 2024 10-Q
— Nov 6, 2024 Risk: medium
Pacira BioSciences, Inc. filed a 10-Q for the period ending September 30, 2024. The filing details financial performance and business operations for the third q -
Pacira BioSciences Files Q2 2024 10-Q
— Jul 30, 2024 Risk: medium
Pacira BioSciences, Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and business operations for the second qua -
Pacira BioSciences, Inc. Files 10-Q for Period Ending March 31, 2024
— May 7, 2024 Risk: medium
Pacira BioSciences, Inc. (PCRX) filed a Quarterly Report (10-Q) with the SEC on May 7, 2024. Pacira BioSciences, Inc. filed a 10-Q report for the period ending
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX